Skip to content
Biosimilars Review & Report

Biosimilars Review & Report

Biosimilars, Biologics, FDA Policy and Approvals, Clinical Trials, and Specialty Pharmacy

  • Biosimilar Approval Status
  • Home
  • About BR&R
  • Biosimilar News and Commentary
  • BR&R Manufacturer Profiles
    • Amgen
    • Amneal Biosciences
    • Samsung Bioepis
  • Contact Us
  • $0.00 0 items

Tag: originator products

Can Biosimilars Be Protected By Patent?

“Are biosimilars patentable?” Sounds like a simple question, right? Well, the answer may not be straightforward, and relate to another question: "Exactly how different are they?"

Stanton Mehr Uncategorized Leave a comment August 15, 2017
  • A summary of the biosimilar products, biosimilar pipeline, and biosimilar strategy of Amgen
  • A summary of the biosimilar products, biosimilar pipeline, and biosimilar strategy of Amneal Biosciences
  • A summary of the biosimilar products, biosimilar pipeline, and biosimilar strategy of Samsung Bioepis
  • A summary of the biosimilar products, biosimilar pipeline, and biosimilar strategy of Amneal Biosciences
  • A summary of the biosimilar products, biosimilar pipeline, and biosimilar strategy of Samsung Bioepis
  • A summary of the biosimilar products, biosimilar pipeline, and biosimilar strategy of Amgen

Recent Posts

  • Biosimilar Education Evolution: Who Educates and Who Updates It? November 11, 2026
  • BsUFA IV: Fee Changes and Program Maturity November 10, 2026
  • Fresenius Kabi Expands Biosimilar Pipeline With Deal for Next-Generation Molecules November 5, 2026
  • Preparations Being Made for Much-Delayed Introduction of Enbrel Biosimilars November 3, 2026
  • Pfizer Oncology Biosimilars’ Falling ASPs October 28, 2026
  • Lower Costs for Biosimilar Development Will Yield Myriad Benefits: Part 2 October 22, 2026
  • Lower Costs for Biosimilar Development Will Yield Myriad Benefits: Part 1 October 21, 2026

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Top Posts & Pages

  • A New Wave of Ustekinumab Biosimilar Launches, Discounted up to 90%
  • BsUFA IV: Fee Changes and Program Maturity
  • Biosimilar Education Evolution: Who Educates and Who Updates It?
  • The Evolution of the Biosimilars Market
  • Biosimilar Approval Status
  • Update on Amgen’s Pavblu Launch Success
  • First Opdivo Biosimilar FDA Application Submitted by Amgen
  • Availability of Top Ranibizumab Biosimilar May be Paused
  • A Conversation With Joshua Fredell, PharmD, Vice President, PBM & Specialty Product Development, CVS Health
  • FDA Commissioner Gottlieb Announces Biosimilars Action Plan
Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.

To find out more, including how to control cookies, see here: Cookie Policy

Follow Us

  • LinkedIn
  • LinkedIn
  • About BR&R
  • Biosimilar Approval Status
  • Contact Us
  • Terms and Conditions
  • Privacy Policy

Copyright

Copyright 2013-2026 by SM Health Communications LLC. All Rights Reserved

Powered by WordPress.com.
Loading Comments...